EKF Launches HbA1c Analyser at Medica 2011

EKF Diagnostics has launched its new HbA1c analyzer at Medica2011, which is in its third day today. The Quo-Lab analyzer is billed as being revolutionary in HbA1c measurement, as it combines world-leading accuracy with low cost, easy to use technology.

The Quo-Lab point of care device uses the same Boronate Affinity techniques as its sister device, Quo-Test. It is small, lightweight and simple to use. The methodology is interference free and is unaffected by haemoglobin variants.

The analyser, designed by EKF subsidiary Quotient Diagnostics, has been specifically developed to provide a point of care device that meets the needs of clinics and laboratories in countries where diabetes is an increasingly large public health issue and resources are limited.

CEO of Quotient Diagnostics, Brian Hickey, says “By using the methodology that we have perfected for Quo-Test, Quo-Lab delivers accuracy, precision and ease of use that will lead the market for HbA1c point-of-care analysers.”

Mr Hickey continued, “Quo-Lab changes the rules of HbA1c measurement because diabetes clinics and laboratories in Asia, Africa and South America will have access to accurate, economic and, most importantly, user-friendly technology.”

Sonia Nicholas, Clinical Diagnostics Editor.